Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-10-25 5:50 pm Purchase | 13G | Inhibikase Therapeutics, Inc. IKT | Sands Capital Life Sciences Pulse Fund II L.P. | 10,950,000 16.300% | 10,950,000 (New Position) | View |
| 2023-06-22 4:32 pm Sale | 13D | DICE Therapeutics, Inc. DICE | Sands Capital Life Sciences Pulse Fund II L.P. | 1,886,470 4.000% | -1,262,500 (-40.09%) | View |
| 2022-11-25 4:25 pm Purchase | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Sands Capital Life Sciences Pulse Fund II L.P. | 1,652,606 7.900% | 1,652,606 (New Position) | View |
| 2021-09-24 6:12 pm Purchase | 13D | DICE Therapeutics, Inc. DICE | Sands Capital Life Sciences Pulse Fund II L.P. | 3,148,970 8.700% | 3,148,970 (New Position) | View |